Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Summary

The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.

Timeline

Start

2022-03-04

Primary completion

2023-06-30

Completion

2023-06-30

Publications

• Lemdani MS, Honig SE, Habarth-Morales TE, Davis HD, Niu EF, Ewing JN, Broach RB, Serletti JM, Percec I. Comparison of Botulinum Toxin A Formulations for Glabellar Strain Treatment in Women: A Double-Blind Randomized Clinical Trial. JAMA Dermatol. 2025 Jul 1;161(7):723-730. doi: 10.1001/jamadermatol.2025.1335.

Drugs

Indications

No indication recorded.